Eyenovia (EYEN) Scheduled to Post Quarterly Earnings on Tuesday

Eyenovia (NASDAQ:EYEN) will be issuing its quarterly earnings data before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

Eyenovia (NASDAQ:EYEN) last released its earnings results on Wednesday, March 27th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.17). On average, analysts expect Eyenovia to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

EYEN stock opened at $6.04 on Friday. Eyenovia has a 12 month low of $2.40 and a 12 month high of $8.96. The company has a market cap of $72.60 million, a P/E ratio of -3.32 and a beta of 1.68.

EYEN has been the subject of several recent research reports. HC Wainwright increased their target price on shares of Eyenovia from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, January 30th. Zacks Investment Research raised shares of Eyenovia from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Finally, Oppenheimer initiated coverage on shares of Eyenovia in a research note on Wednesday, April 24th. They set an “outperform” rating and a $9.00 target price for the company.

ILLEGAL ACTIVITY WARNING: This article was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/12/eyenovia-eyen-scheduled-to-post-quarterly-earnings-on-tuesday.html.

About Eyenovia

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

See Also: What is the Quick Ratio?

Earnings History for Eyenovia (NASDAQ:EYEN)

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.